By Stacy M. Brown, NNPA Newswire Senior National Correspondent Company officials have announced that Moderna’s COVID-19 vaccine generated a robust immune response and was generally well-tolerated in children aged six to 11 years. The pharmaceutical giant plans to submit its findings later this week to federal regulators. Moderna reported that its two-dose vaccine generated virus-neutralizing […]
